Investigations closed for companies suspected of cytostatics' price fraud

It's about companies “

However, in a document provided by Indexline, it is known that investigative procedures on these companies have been closed that had opened on May 4th of last year.

This, since the Commission of the Kosovo Competition Authority has found there is no evidence of a bidding scheme.

“Shut down investigative procedure to Ntsh “Redo H M”, “Exlusive Corporation” shpk and “Exclusive” Now, open to conclusion number 31/18 of d 04.05.2018” The Kosovo Competition Authority Commission finds there is no evidence that companies under investigation have set up bids at the Health Ministry's tenders for medicine supplies from the Essencial List ) bar Imatinib Malite 400 m<8>, the decision said.

The decision states that authority following concerns raised by the minister and the media has begun handling the case according to official duty, broadcast Indexline/

Health Minister Uran Ismaili has announced the Competition Authority for His Doubts on the MSH “Fournisation With Cito static List from ESencial List” Llot 17, with suspicion of limiting competition with agreements prohibited by companies in the procurement process at the Ministry of Health.

The authority, after preliminary review of the investigation, has come to the conclusion that there are doubts about secret agreements between bidders and that investigative procedures for the Health Ministry tenders should be launched, respectively, contracts, MSH public framework contracts for cytostatic supply, the Llots designated over years in tenders for the Imatinb Mesajate 400 mg bar.

Kosovo Competition Authority under the Law for Protection of Competition, Article 66: “Implementation of this law should be in line with the directives of the European Union” so we consulted O Guide ECD “Mbi combating prohibited agreements in public procurement bids@x4> to prove whether companies under investigation used the Rotation principle to win tenders for supplies from the Essencial List for the Imatinib Mesyate 400mg bar at the Ministry of Health. According to this OECD guidance guide, in the rules of the rotating bidding principle, companies involved in generating/manipulating bids agree to compete, but one to withdraw from being the winning tender (usually the lowest price bidder), which this time releases the other company's line)”, says in this decision, it broadcasts Indexline.

Based on this methodology, the behavior of economic operators (competers) who had been offered to the Ministry of Health by economic operators “Nsh “Redo H”, “Exclusive Corporation” shpk and “Exclusive” Go.

The Exclusive Company Shpch product Imatinib 400 mg has sold at the price of which it has contracted with the Ministry of Health, while after completing the contract with this institution it has sold at a cheaper price, according to the statement of representatives of the 5 Exclusve Company Shpch the reason for the sale of the price has been due to: pharmaceutical products have an expiration deadline of 1-3 years, while the bar Imatinb Mesilate 400mg has a 5-year term, this is important at the price, because pharmaceutical companies estimate that we sell the product at the lowest price, because it's the cost of destruction.

While the company Ntsh “Redon H”, the Imatinib medium-400 mg product has not sold by retail but only by large in those institutions with which it is contracted.

Based on this, the Competition Authority in the tender for supply from the essential drug list for the Imatinib 400 mg bar has concluded that companies have not won rough tenders for quantity and price, according to the price and quantity it is not rough to ascertain that companies have been co-ordinated, although we have apparently listed tenders in the Ministry of Health, but economic reasoning does not comply with the goal because the rotating principle would have been implemented to match the price of contracts and supply.